← Leaderboards
Laura K Aguilar
Advantagene, Inc
$1,149,301
Attributed
$2,298,601
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $659.5K · FY2016–21$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$2,298,601 · 1
By mechanism
R44$2,298,601 · 1
Top collaborators
- Estuardo Aguilar-Cordova5 shared
Most similar at Advantagene, Inc
Same institution · by research overlap
- Estuardo Aguilar-Cordova$12,245,489
- Douglas J. Jolly$482,896
Others in their field
Top investigators on “Malignant Glioma”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
- David Heimbrook · Leidos Biomedical Research, Inc.$56,561,099
- Gregory H Reaman · National Childhood Cancer Foundation$31,993,642
- Melissa L Bondy · Stanford University$28,908,234
- Brad H. Pollock · University Of Florida$28,646,726
Research focus
Malignant GliomaOperative Surgical ProceduresGenesImproved OutcomeMediatingNeoadjuvant TherapyDoseGemcitabineCytotoxicImmunotherapyMalignant Neoplasm Of PancreasMeasurableMicrometastasisChemoradiationChemotherapyCytokineExcisionClinical ProtocolsClinical ResearchClinical TrialsGrantImmuneCurative TreatmentsPalliative Chemotherapy
Grant awards (5)
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$611,350
R44 · FY2021 · CA
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$611,350
R44 · FY2020 · CA
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$116,400
R44 · FY2019 · CA
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$659,516
R44 · FY2018 · CA
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation$299,985
R44 · FY2016 · CA